Amylyx Pharmaceuticals’ Q4 2024 Earnings Conference Call: Key Highlights
On March 4, 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) held its Fourth Quarter and Full-Year 2024 Earnings Conference Call. The call was led by Lindsey Allen, Head of Investor Relations and Communications, Josh Cohen and Justin Klee, Co-CEOs, Camille Bedrosian, Chief Medical Officer, and Jim Frates, Chief Financial Officer. Michael DiFiore from Evercore ISI and Joe Beatty from Baird were among the conference call participants.
Financial Performance
Jim Frates shared the financial highlights of the quarter. Total revenue for Q4 2024 was reported at $125.5 million, a significant increase from $77.8 million in the same quarter the previous year. The net loss for the quarter was $29.6 million, compared to a net loss of $32.1 million in Q4 2023. The full-year revenue for 2024 was reported at $412.3 million, a substantial growth from $245.6 million in 2023.
Product Updates
Camille Bedrosian provided updates on the company’s product pipeline. Amylyx announced that it had submitted a New Drug Application (NDA) to the FDA for AMX0035, its treatment for Amyotrophic Lateral Sclerosis (ALS), in late 2024. The company also shared that it had initiated a Phase 3 clinical trial for its treatment for Fabry Disease, AMX0039, in Q3 2024.
Collaborations and Partnerships
Josh Cohen and Justin Klee discussed the company’s collaborations and partnerships. They announced that Amylyx had entered into a strategic collaboration with Biogen to develop and commercialize AMX0035 in Europe and other markets outside of the United States. The companies will share profits and losses on a 50/50 basis.
Impact on Individuals
The announcement of Amylyx’s financial performance, product updates, and collaborations has significant implications for individuals affected by the diseases that the company is targeting. For those living with ALS, the submission of the NDA for AMX0035 brings hope for a potential new treatment option. The initiation of the Phase 3 clinical trial for AMX0039 offers similar hope for those with Fabry Disease. Furthermore, the partnership with Biogen could lead to wider access to AMX0035 for individuals in Europe and other regions.
Impact on the World
The progress made by Amylyx Pharmaceuticals in the development of treatments for ALS and Fabry Disease has the potential to significantly impact the healthcare landscape. According to the ALS Association, there are approximately 5,000 people in the United States living with ALS, and the disease affects people in more than 60 other countries. Fabry Disease, a rare genetic disorder, affects an estimated 1 in 40,000 to 1 in 117,000 people worldwide.
The submission of the NDA for AMX0035 and the initiation of a Phase 3 clinical trial for AMX0039 bring new hope for these patient populations. Furthermore, the partnership with Biogen could lead to wider access to AMX0035 for individuals in Europe and other regions, potentially improving the quality of life for thousands of people living with these diseases.
Conclusion
Amylyx Pharmaceuticals’ Q4 2024 Earnings Conference Call provided valuable insights into the company’s financial performance, product pipeline, and collaborations. The submission of the NDA for AMX0035 and the initiation of a Phase 3 clinical trial for AMX0039 bring hope for those living with ALS and Fabry Disease. The partnership with Biogen could lead to wider access to AMX0035 for individuals in Europe and other regions, potentially improving the quality of life for thousands of people. The progress made by Amylyx Pharmaceuticals has the potential to significantly impact the healthcare landscape and offers a promising future for the treatment of these diseases.
- Amylyx Pharmaceuticals reported a significant increase in revenue for Q4 2024 and full-year 2024
- AMX0035, a treatment for ALS, has been submitted for FDA approval
- Phase 3 clinical trial initiated for AMX0039, a treatment for Fabry Disease
- Amylyx entered into a strategic collaboration with Biogen to develop and commercialize AMX0035 in Europe and other regions
- The progress made by Amylyx Pharmaceuticals has the potential to significantly impact the healthcare landscape and offer hope for thousands of people living with ALS and Fabry Disease
